This study designs novel 2-benzamido-N-(4-substituted phenyl)thiophene-3-carboxamide derivatives as selective COX-2 inhibitors. Compound VIIa showed strong in vitro anti-inflammatory activity, and incorporating it into niosomes improved its release profile for future in vivo use.